$26.37
+0.65 (+2.53%)
Open$26.25
Previous Close$25.72
Day High$29.50
Day Low$26.09
52W High$35.62
52W Low$4.90
Volume—
Avg Volume223.2K
Market Cap379.32M
P/E Ratio—
EPS$-4.49
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
-69.8% upside
Current
$26.37
$26.37
Target
$7.97
$7.97
$5.39
$7.97 avg
$9.61
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 320.9K | 345.6K | 44.14M |
| Net Income | -152,009,038 | -147,374,915 | -12,888,213 |
| Profit Margin | -158,800.0% | -150,860.0% | -29.2% |
| EBITDA | -151,839,100 | -155,388,500 | -17,594,581 |
| Free Cash Flow | — | — | -11,802,396 |
| Rev Growth | -7.2% | -7.2% | -3.2% |
| Debt/Equity | — | — | 0.27 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |